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We are told in the preface to this volume - a collection of reviews ostensibly concerned with oncogene ac- 
tivation but which, fortunately for the reader, actually deals with all aspects of oncogenology - that the 
idea behind the book was to resolve once and for all the Bishop/Duesberg controversy. Duesberg proposed 
in 1985 the categorical imperative that viral transduction and modification is required for oncogene 
tumorigenicity. Well, it is sometimes difficult to know what to put in these book prefaces and we must 
forgive the editor for dragging up ancient quarrels to fill the page. Not many paid much attention at the 
time and certainly no one in 1987, the year these reviews were assembled, would give any credence to 
Duesberg’s view. Bishop’s ‘enemy from within’ hypothesis now holds full sway and certainly some of the 
more recent oncogenes to come to our attention having been discovered by the transfection technique using 
human or rat tumour DNA, for example met and neu, show no evidence of having been kissed malevolently 
by a virus. 
No, the real controversy that pervades these pages concerns the ‘protooncogene’; not a new unicellular 
organism, but the primordial cellular gene from which a viral oncogene is derived. Should it have a hyphen 
or should it not? Some feel that it should not since the simpler spelling would give our Japanese colleagues 
some marvellous opportunities for malapropisms to relieve the boredom of a dull day at the Conference. 
However, editor George is obviously keeping a foot in both camps - he uses either form almost at random 
in his presentation. 
Many who took a serious interest in this field during the heady halcyon days of the weekly Nature on- 
cogene reviews have become somewhat perplexed of late. Oncogenes eem to breed with Malthusian vigour. 
The mycs, the erbs, the rms, the STCS, the abls we know and recognise, but what exactly are all these 
newfangled trks, kits and rets? To such readers, and I count myself as one, this book is directed. Not only 
are the newly researched shenanigans of our old oncogene friends described but we are also enlightened as 
to the derivation and possible function of all the latest additions. This is of great help. The times when one 
could pick up the journal Cell and read a comprehensive review on the whole field are long gone by because 
the accumulation of knowledge is so vast. For example, each of the 12 papers in this edition quotes on 
average about 150 titled references almost all from the period 1983-1987. 
Having thankfully made that statement, now the caveats. Exempting Messrs. Mtiller et al. whose con- 
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tribution on the cellular oncogenes encoding nuclear proteins fos, myb, myc and e&l is one of the clearest 
and more readable chapters in the book, there appears to be a considerable dearth of attempts by authors 
to illustrate the structure of the genes, that they discuss in such assiduous detail, by even a lone diagram. 
This may be excused in their latest for Proc. Natl. Acad. Sci. USA but surely not in a review. And after 
the compulsory introductory paragraph or two, there is a tendency to plunge straight into research detail 
and jargon. 
Another disappointment is that, despite the fact that much is now known about certain domain structures 
in oncogene proteins and their proto-oncogene ncoded relatives, there are no explanatory figures or draw- 
ings. Not a single DNA-binding zinc finger (found in c-fos and erbB proteins)... not a single phosphoryl 
binding loop from the GDP/GTP binding site of the ras family.. . not a single cysteine cluster from the exter- 
nal domain of the growth factor receptors (related to erbB and neu) brightens a page for the word-weary 
reader. Perhaps this reflects a desire of the modern oncogenologist o stay amongst clean straightforward 
DNA sequences and not to get his or her hands messy with proteinaceous ooze or to have to set up a DEAE 
column. Failure to illustrate structural points, and this book is mainly about structure of genes and their 
products, has, I feel, reduced the book’s readership window and that is a pity and an opportunity missed. 
But perhaps the creation I have in mind could only be put together by a single author. How about it, Bill? 
Many who labour in the cancer field, particularly on the clinical side, will be wondering: ‘is there anything 
there for me?’ Such workers grant that oncogenes are a new and exciting area of fundamental research but 
are waiting... and waiting.. for something useful to emerge - useful to the patient, that is. In this regard, 
two areas covered in depth may be of interest. It is now clear why most chronic myeloid leukaemia patients 
carry the characteristic abnormal chromosome called the Philadelphia chromosome. De Klein et al. describe 
how the chromosome translocation that creates this new marker has moved the c-abl gene into a new posi- 
tion and placed it under the control of a different promoter and regulatory system - that of the bcr gene. 
The protein translated from this fused, chimeric gene product has been isolated and characterised and, 
almost certainly, it is this that induces tumour formation. Similar information has been worked out for 
Burkitt’s lymphoma where c-myc DNA is translocated to lie near an immunoglobulin enhancer. Polack and 
Eick relate how this can happen in a variety of ways all of which appear to have exactly the same re- 
sult - a lymphoma in the neck of a child in Africa or New Guinea. 
A fascinating chapter by Collins and Groudine discusses the unfolding role of oncogene DNA amplifica- 
tion in human tumours. Although it is not a common event, in the tumour types in which it does occur 
the extent of amplification can be readily determined in biopsies by a simple hybridization assay. It turns 
out that the degree of amplification is related to the stage of tumour development. This assay may therefore 
become an important diagnostic tool for the clinician. Staging a tumour is vitally important in deciding 
upon appropriate treatment. So let’s hear it for oncogenes! 
The volume will be welcomed by the many who would like to update their oncogene knowledge circa 1987 
and it can be recommended for all who wish to find out about the nuts and bolts of this fascinating and 
rapidly advancing area. Beginners, however, may find some of the presentations a trifle bleak. 
C. J. Chesterton 
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